Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182127 | 0.87 | CRHR1 (0.61) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL2931339 | 0.85 | CRHR1 (0.52) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL2496095 | 0.83 | CRHR1 (0.49) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL29430976 | 0.82 | CRHR1 (0.57) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL2494849 | 0.81 | CRHR1 (0.48) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL2932900 | 0.81 | CRHR1 (0.47) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL2180543 | 0.80 | CRHR1 (0.54) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL22958804 | 0.79 | CRHR1 (0.56) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL25490371 | 0.78 | CRHR1 (0.56) | CRHR1CRHR2KMT2APOLBHSD17B10 | |
| SCHEMBL25490375 | 0.77 | CRHR1 (0.49) | CRHR1CRHR2KMT2APOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12576084-B2 | Methods for treating testicular and ovarian adrenal rest tumors | SPRUCE BIOSCIENCES, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4656192-A3 | TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12569491-B2 | Methods for treating testicular and ovarian adrenal rest tumors | SPRUCE BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569490-B2 | Methods for treating testicular and ovarian adrenal rest tumors | SPRUCE BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2026047334-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2026-03-05 | — | — | WO | disclosed |
| EP-4656192-A2 | TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4656192-A2 | TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4643950-A2 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | Spruce Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025188842-A8 | AMORPHOUS SOLID DISPERSION OF TILDACERFONT FORMULATIONS | SPRUCE BIOSCIENCES, INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-09-21 | — | — | US | disclosed |
| WO-2023163945-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND POLYCYSTIC OVARY SYNDROME | Crinetics Pharmaceuticals, Inc. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11708372-B2 | Crystalline composition of tildacerfont and methods of use and preparation thereof | SPRUCE BIOSCIENCES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116322544-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230159533-A1 | CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-05-25 | — | — | US | disclosed |
| WO-2023091684-A1 | CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF | SPRUCE BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091684-A1 | CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF | SPRUCE BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4175572-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220211711-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-07-07 | — | — | US | disclosed |
| US-11304950-B2 | Methods for treating testicular and ovarian adrenal rest tumors | SPRUCE BIOSCIENCES, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576084-B2 | Methods for treating testicular and ovarian adrenal rest tumors | MC2R, GNRHR, CRH | CRHR1 6/4885CRHR2 7/4885KMT2A 1204/4885 |
| US-11304950-B2 | Methods for treating testicular and ovarian adrenal rest tumors | NR5A1, SHBG, CYP17A1 | CRHR1 50/4885CRHR2 61/4885KMT2A 1377/4885 |
| US-12569490-B2 | Methods for treating testicular and ovarian adrenal rest tumors | MC2R, GNRHR, CRH | CRHR1 5/4885CRHR2 7/4885KMT2A 1149/4885 |
| US-20230159533-A1 | CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF | CRHR1, CRH, MC2R | CRHR1 1/4885CRHR2 4/4885KMT2A 4760/4885 |
| US-11708372-B2 | Crystalline composition of tildacerfont and methods of use and preparation thereof | CRH, CRHR1, MC2R | CRHR1 2/4885CRHR2 4/4885KMT2A 4640/4885 |
| US-12569491-B2 | Methods for treating testicular and ovarian adrenal rest tumors | MC2R, CRH, CRHR1 | CRHR1 3/4885CRHR2 5/4885KMT2A 1507/4885 |
| US-20220211711-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | NR5A1, SHBG, CYP17A1 | CRHR1 50/4885CRHR2 61/4885KMT2A 1377/4885 |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885CRHR2 239/4885KMT2A 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.